What is the difference between GLP-3 (Reta) and Semaglutide?

The main difference is mechanism and research stage. GLP-3 (Reta) targets GLP-1 + GIP + glucagon (triple agonist) (phase 3 (investigational)) and is studied for metabolic & body-weight research; Semaglutide targets GLP-1 (mono agonist) (approved formulations exist) and is studied for metabolic & body-weight research. Both are research-use-only compounds, not for human or animal use.

Are GLP-3 (Reta) and Semaglutide approved for human use?

No. Renova Wellness supplies both strictly for in-vitro laboratory and scientific research use only. Research status differs — GLP-3 (Reta): phase 3 (investigational); Semaglutide: approved formulations exist — but neither is sold for human or animal consumption, and no medical, therapeutic, or dosing claims are made.

How is purity verified for GLP-3 (Reta) and Semaglutide?

Every lot of both compounds ships with its own per-batch Certificate of Analysis — identity by mass spectrometry, ≥98% purity by HPLC, and a unique lot number you can verify against the vial in your hand.

Research Comparison

GLP-3 (Reta) vs Semaglutide

GLP-3 (Reta) and Semaglutide are often compared because both sit in metabolic research. GLP-3 (Reta) acts on GLP-1 + GIP + glucagon (triple agonist) and is studied for metabolic & body-weight research, while Semaglutide acts on GLP-1 (mono agonist) and is studied for metabolic & body-weight research. Both are supplied as lyophilized powder for in-vitro laboratory research only — this page compares mechanism and research status, not dosing or human use.

GLP-3 (Reta)

Metabolic

Semaglutide

Metabolic

Frequently asked

What is the difference between GLP-3 (Reta) and Semaglutide?: The main difference is mechanism and research stage. GLP-3 (Reta) targets GLP-1 + GIP + glucagon (triple agonist) (phase 3 (investigational)) and is studied for metabolic & body-weight research; Semaglutide targets GLP-1 (mono agonist) (approved formulations exist) and is studied for metabolic & body-weight research. Both are research-use-only compounds, not for human or animal use.
Are GLP-3 (Reta) and Semaglutide approved for human use?: No. Renova Wellness supplies both strictly for in-vitro laboratory and scientific research use only. Research status differs — GLP-3 (Reta): phase 3 (investigational); Semaglutide: approved formulations exist — but neither is sold for human or animal consumption, and no medical, therapeutic, or dosing claims are made.
How is purity verified for GLP-3 (Reta) and Semaglutide?: Every lot of both compounds ships with its own per-batch Certificate of Analysis — identity by mass spectrometry, ≥98% purity by HPLC, and a unique lot number you can verify against the vial in your hand.

Key research terms

GLP-3 (Reta) guide Semaglutide guide GLP-1 GIP Glucagon Agonist Half-Life Reconstitution

Related comparisons

GLP-3 (Reta) vs GLP-2 (Tirz)Semaglutide vs GLP-2 (Tirz)

Build a multi-compound set in the Stack Builder or run the reconstitution calculator.

Research references

Primary literature for GLP-3 (Reta) and Semaglutide. Provided for scientific context only — not medical or dosing guidance.

Jastreboff AM, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023. PMID 37366315 →
Rosenstock J, et al. Retatrutide for people with type 2 diabetes: a randomised phase 2 trial. Lancet. 2023. PMID 37385280 →
Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021. PMID 33567185 →
Amaro A, et al. Cardiometabolic risk factors efficacy of semaglutide in the STEP program. Postgrad Med. 2022. PMID 36691308 →

Research use only. This comparison covers mechanism, target, and research status. It is not medical, therapeutic, or dosing advice. Compounds sold by Renova Wellness™ are for in-vitro laboratory research and are not for human or animal consumption.